Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients.

@article{Sato2012NeutralizingAA,
  title={Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients.},
  author={Douglas Kazutoshi Sato and Ichiro Nakashima and Toshiyuki Fukazawa and Yuko Shimizu and Yuji Tomizawa and K Yokoyama and Tatsuro Misu and Paul I. Creeke and Rachel Farrell and Gavin Giovannoni and Y. Itoyama and Kazuo Fujihara and Masashi Aoki},
  journal={The Tohoku journal of experimental medicine},
  year={2012},
  volume={228 2},
  pages={85-92}
}
Multiple sclerosis (MS) is a chronic immune-mediated inflammatory demyelinating disease of the central nervous system. Interferon-β (IFN-β) has been used as the first line therapy for MS treatment in Japan, but patients treated with IFN-β may develop antibodies, known as neutralizing antibodies (NAbs), which abrogate its therapeutic effects. Intramuscular IFN-β 1a and subcutaneous IFN-β 1b are currently available in Japan, but large-scale studies evaluating the prevalence and clinical… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Evaluation of the impact of neutralizing antibodies on IFNβ response.

Clinica chimica acta; international journal of clinical chemistry • 2015
View 2 Excerpts

Similar Papers

Loading similar papers…